Affinia Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
43 Foundry Ave Ste 120, Waltham, Massach...Phone Number
(617) 430-7817Website
www.affiniatx.comRevenue
<$5 MillionIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
3
1
1
1
2
About Affinia Therapeutics
Founded in 2019, Affinia Therapeutics is a preclinical stage biotechnology company developing a class of rationally-designed gene therapies that treat rare and prevalent diseases. They are based in Waltham, Massachusetts.Explore more
Affinia Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Affinia Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Affinia Therapeutics
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Affinia Therapeutics has new funding data
Earning: See what the market has to say on Affinia Therapeutics recently announced quarterly report
Click to see if Affinia Therapeutics had a recent Job posting/layoffs
Check if Affinia Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Affinia Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Affinia Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Affinia Therapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Affinia Therapeutics
Compare insights from companies similar to Affinia Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Affinia Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Affinia Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Affinia Therapeutics.
Affinia Therapeutics financials insights
Gather financial insights about Affinia Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$60M
2021
Series B
$110M
2025
Series C
$40M
Stock/Share Issuance
$13.3M
Affinia Therapeutics Tech Stack
A closer look at the technologies used by Affinia Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Search, Medical Research, Pharmaceuticals, Clinical Operations, Operations
Affinia Therapeutics News & Media
Affinia Therapeutics Announces Series C Financing to Advance New Class of Gene ...
WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-classAffinia Therapeutics and DCM Foundation Announce Partnership to Increase Awareness About BAG3 Dilated Cardiomyopathy and Critical Need for Genetic Testing to Help Save Lives
WALTHAM, Mass. & DUBLIN, Ohio--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies for devastating cardiovascular and neurological diseases, and the DCM Foundation together with the Genetic Cardiomyopathy Awareness Consortium (GCAC), today announced they have joined forces to raise awareness about BAG3 dilated cardiomyopathy (DCM), with the goal of promoting earlyAffinia Therapeutics Presents New Data on its Lead AFTX-201 Program in BAG3 Dilated Cardiomyopathy, BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Technology at the 28th American Society of Gene & Cell Therapy 2025 Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies for devastating cardiovascular and neurological diseases, today announced the presentation of new preclinical data on AFTX-201, its lead program for BAG3 dilated cardiomyopathy (DCM), as well as its novel AAV capsids for diseases of the central nervous system (CNS), and the company’s high-yield maAffinia Therapeutics to Present New Data on its AFTX-201 Program in BAG3 Dilated Cardiomyopathy, BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Technology at the 28th Annual American Society of Gene & Cell Therapy 2025 Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies for devastating cardiovascular and neurological diseases, today announced that new preclinical data on AFTX-201, its lead program for BAG3 dilated cardiomyopathy (DCM), as well as its novel AAV capsids for diseases of the central nervous system (CNS), and the company’s high-yield manufacturing pro
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Affinia Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2019, Affinia Therapeutics is a preclinical stage biotechnology company developing a class of rationally-designed gene therapies that treat rare and prevalent diseases. They are based in Waltham, Massachusetts.... Read More
